Lower Contribution of Factor V Leiden or G202104 Mutations to Ischemic Stroke in Patients With Clinical Risk Factors

Abstract

It was suggested that factor V Leiden and prothrombin G20210A mutations increase the risk of ischemic stroke only in combination with clinical risk factors of arterial ischemic disease. In these studies the controls were derived from the general population, with fewer clinical risk factors, which might have produced biased results. The factor V Leiden and prothrombin G20210A mutations were examined by polymerase chain reaction technique in 120 ischemic stroke patients and 120 controls younger than 65 years of age. Each patient had his own control, tightly matched in clinical risk factors. The prevalences of factor V Leiden and prothrombin G20210A mutations in patients were 8.3% (P = 0.02) and 7.5% (P = 0.04), respectively, and 2.5% for controls for both mutations. All carriers were single heterozygotes. In patients, but not in controls, the carriers of either mutation were mostly women and with fewer clinical risk factors for arterial ischemic events. In particular, considering both mutations as a single coagulation deficit, their presence increased the likelihood of ischemic stroke (odds ratio [OR] = 3.6; 95% confidence interval [CI] 1.4—9.3), especially among women (OR = 4.6; 95% CI: 1.2—17.8), normotensive persons (OR = 9.2; 95% CI: 1.1—17.8) and those having normal cholesterol (OR = 5.9; 95% CI: 1.6—21.2) and triglyceride serum concentrations (OR = 4.3; 95% CI: 1.5—12.8). In the studied sample of adult North Mediterranean population younger than 65 years the prevalences of factor V Leiden and prothrombin G20210A mutations were greater in patients with ischemic stroke than in matched controls. Unlike in studies with unmatched controls, we observed an apparently negative interaction of these mutations with clinical risk factors.

Keywords

Factor V Leiden G20210A Stroke.

References

Swensson PJ , Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517.

Poort SR , Rosendaal FR , Reitsma PH , Bertina RM A common genetic variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698.

Kim RJ , Becker RC Association between factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase C677T mutations a events of the arterial circulatory system: A meta-analysis of published studies. Am Heart J 2003;146:948.

Szolnoki Z. , Somogyvári F. , Kondacs A. , et al. Evaluation of the modifying effects of unfavourable genotypes on classical clinical risk factors for ischaemic stroke. J Neurol Neurosurg Psychiatry 2003; 74:1615.

Concato J. , Feinstein AR , Holford TR The risk of determining risk with multivariate models. Ann Intern Med 1993;118:201.

Zöller B. , Svensson PJ , He X. , Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis: Prone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521.

Kirkwood BR Essentials of Medical Statistics. Oxford: Blackwell Scientific Publications; 1988.

Hassan A. , Markus HS Genetics and ischemic stroke. Brain 2000;123:1784.

Szolnoki Z. , Somogyvári F. , Kondacs A. , Szabó M. , Fodor L. Evaluation of the roles of the Leiden mutation and ACE/I/D polymorphism in subtypes of ischaemic stroke. J Neurol 2001 ;248:756.

10.

MacCallum PK , Cooper JA , Howarth DJ , Meade TW , Miller GJ Sex differences in the determinants of fibrinolytic activity. Thromb Haemost 1998;79:587.

11.

Gebara OC , Mittleman MA , Walsh BW , et al. Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia. Heart 1998;80:235.